DUBLIN, April 26, 2016 /PRNewswire/ —
Research and Markets has actually announced the addition of the “Form 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Intake of Newer Therapies and Expanding Treatment Population to Promote Robust Growth” report to their offering.
(Logo: http://ift.tt/1UURArF )
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to enhance in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – higher blood glucose levels – that outcomes from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated along with lasting damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels.
The vast majority of diabetes mellitus patients can easily be classified as having either Form 1 Diabetes Mellitus (T1DM) or Form 2 Diabetes Mellitus (T2DM). Roughly 85-95% of all of diabetics have actually T2DM.
T2DM treatment has actually been revolutionized in the past decade, especially along with the increased usage of Brand-new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies.
Nevertheless, considerable unmet requirement remains for products that can easily provide much better glycemic regulate also as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardio disease.
Scope
The current T2DM in the Asia-Pacific (APAC) market consists of novel products, including Jardiance – a SGLT-2 inhibitor; Victoza – a GLP-1 receptor agonist; and Galvus – a DPP-4 inhibitor.
– Just what are the competitive benefits of the existing novel drugs?
With over 500 energetic pipeline molecules, a lot of of the late-phase investigational drug candidates are being evaluated, featuring improved dosing routines and administration routes, in comparison to currently marketed products and combination therapies.
– Which classes of novel drugs are a lot of prominent within the pipeline?
– Is there sturdy potential for the pipeline to treat unmet requires within the T2DM market?
Analysis of clinical trials, due to the fact that 2006, identified that the failure paces of T2DM molecules were highest in Phase II, at 54%, along with the general attrition fee for T2DM at 82.6%.
– Exactly how do failure paces vary by product phase of development, molecule type, and mechanism of action?
– Exactly how do others factors, such as standard trial duration and trial dimension motivate the costs and pitfalls associated along with product development?
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 ailment Overview
2.2 Classification
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.6 Epidemiology
2.7 Prognosis
2.8 Co-morbidities and Complications
2.9 Diagnosis
2.10 Assessing Treatment Effectiveness
2.11 Treatment
2.11.1 Non-insulin T2DM Therapies
2.11.2 Insulin T2DM Therapies
2.12 Treatment Segments
2.12.1 Non-insulin therapies
2.12.2 Insulin Therapies
3 Marketed Products
3.1 Overview
3.2 Biguanides
3.2.1 Metformin
3.3 Sulfonylureas
3.4 Thiazolidinediones
3.4.1 Pioglitazone
3.5 GLP-1 receptor agonists
3.5.1 Byetta (exenatide)
3.5.2 Bydureon (exenatide)
3.5.3 Victoza (liraglutide)
3.5.4 Lyxumia (lixisenatide)
3.5.5 Tanzeum (albiglutide)
3.5.6 Trulicity (dulaglutide)
3.6 DPP-4 Inhibitors
3.6.1 Januvia/Glactiv (sitagliptin)
3.6.2 Galvus (vildagliptin)
3.6.3 Onglyza (saxagliptin)
3.6.4 Trazenta (linagliptin)
3.6.5 Zafatek (trelagliptin succinate)
3.6.6 Marizev (omarigliptin)
3.7 SGLT-2 Inhibitors
3.7.1 Forxiga (dapagliflozin)
3.7.2 Invokana (canagliflozin)
3.7.3 Jardiance (empagliflozin)
3.8 Insulin Therapies
3.8.1 Lantus (insulin glargine)
3.8.2 Levemir (insulin detemir)
3.8.3 Tresiba (insulin degludec)
3.8.4 Toujeo/ Lantus XR (insulin glargine)
3.9 Marketed Products Heat Maps
4 Pipeline
4.1 Overview
4.2 Pipeline Distribution by phase of Development, Molecule Form and Routine Type
4.3 Pipeline Distribution by Molecular Target
4.4 Clinical Trial Landscape
4.5 Promising Pipeline Molecules
4.5.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) – Novo Nordisk
4.5.2 ITCA 650 – Intarcia Therapeutics
4.5.3 Ertugliflozin – Pfizer
4.6 Pipeline Products Heat Map
5 Market Forecast to 2021
5.1 Geographical Markets
5.2 Asia-Pacific Markets
5.3 China
5.4 India
5.5 Australia
5.6 Japan
5.7 Drivers and Barriers for the T2DM Therapeutics Market
6 Strategic Consolidations
6.1 Licensing Deals
6.1.1 AbbVie Collaborates along with Halozyme Therapeutics to Bank on its ENHANZE Technology
6.1.2 Janssen Collaborates along with Halozyme Therapeutics to Bank on its ENHANZE Technology
6.1.3 Emisphere Signs Licensing Agreement along with Novo Nordisk to make Oral Formulations Targeting Metabolic Indications
6.1.4 Amunix Announces Exclusive Agreements along with Naia to make GLP-1 and GLP-2 XTEN Products
6.2 Co-improvement Deals
6.2.1 Intarcia Therapeutics Goes into in to Co-improvement Agreement along with Servier for ITCA 650 (DUROS delivery exenatide)
6.2.2 Merck Goes into in to Co-improvement Agreement along with Pfizer for ertugliflozin
6.2.3 AstraZeneca Goes into in to Research Agreement along with Inserm
6.2.4 Intarcia Therapeutics Goes into in to Co-improvement Agreement along with Numab
6.2.5 AstraZeneca Goes into in to Co-improvement Agreement along with Bristol-Myers Squibb
7 Appendix
Companies Mentioned
– AbbVie
– Amunix
– AstraZeneca
– Bristol-Myers Squibb
– Emisphere
– Halozyme Therapeutics
– Intarcia Therapeutics
– Janssen
– Merck
– Naia
– Novo Nordisk
– Numab
– Pfizer
For a lot more short article visit http://ift.tt/1TbexBj
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hrs Call 1-917-300-0470
For U.S./can easily Toll Free Call 1-800-526-8630
For GMT Office Hrs Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
